New Cryopreservation Technology of hMSCs: First Preclinical Results Using DMSO-containing Medium
J Miroslava1, S Pavel2, V Doris3
1Tissue Bank, University Hospital Hradec Kralove; Department of Histology and Embryology, Faculty of Medicine in Hradec Kralove, Charles University, Czech Republic. jandomir@fnhk.cz.
Cryo Letters
|May 11, 2021
Summary
Cryopreserved human mesenchymal stem cells (hMSCs) maintain high viability and acceptable cell purity after thawing. These findings support the use of cryopreserved hMSCs as advanced therapy medicinal products (ATMPs) for regenerative medicine applications.
Area of Science:
- Regenerative Medicine
- Cell Biology
- Cryopreservation
Background:
- Human mesenchymal stem cells (hMSCs) show significant promise for regenerative medicine.
- Cryopreservation and banking of hMSCs are crucial for enhancing their accessibility and availability.
Purpose of the Study:
- To evaluate the quality of cryopreserved human mesenchymal stem cells (hMSCs) for use as advanced therapy medicinal products (ATMPs).
- To compare the characteristics of fresh and cryopreserved hMSCs within a clinical trial context for patients undergoing hip replacement.
Main Methods:
- Assessed cell viability using the trypan blue exclusion test.
- Utilized flow cytometry for cell viability and phenotyping.
- Determined cell proliferation via clonogenic assay and assessed sterility.
Main Results:
- Cryopreserved hMSCs demonstrated good quality parameters post-thaw compared to fresh cells.
- Viability exceeded 90% in all cases when using dimethyl sulfoxide (DMSO) containing medium.
- Cell purity, as assessed by flow cytometry, was found to be acceptable.
Conclusions:
- The cryopreserved advanced therapy medicinal product (ATMP) exhibited favorable viability and phenotype characteristics.
- These initial results indicate the potential of cryopreserved hMSCs for therapeutic applications.
